Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

AI-based infectious diseases diagnosis in seconds

Descrizione del progetto

L’IA per una rapida diagnosi delle malattie infettive

Le malattie infettive non vengono identificate in modo attendibile a causa di una carenza di capacità di diagnosi. Un numero crescente di agenti infettivi non può essere identificato facilmente ed efficacemente senza test di laboratorio. Di conseguenza, i medici prendono in considerazione i sintomi e tendono a prescrivere antibiotici. Un tale metodo, tuttavia, non rileva se la causa della malattia si basi su batteri o virus, portando a prescrizioni farmacologiche inappropriate. Il progetto EDAS HEALTHCARE, finanziato dall’UE, propone un sistema di diagnosi delle malattie infettive basato sui dati che è il risultato di 5 anni di ricerca. Questa tecnologia avanzata si basa su una combinazione di megadati e algoritmi di apprendimento automatico e consente la diagnosi di agenti patogeni in pochi secondi e a un costo inferiore rispetto ai normali test di laboratorio.

Obiettivo

Today, reliable diagnosis of infectious diseases is not available at the Point-Of-Care, when most needed, resulting in Antimicrobial Resistance, High Treatment Costs and Patients’ Dissatisfaction. A growing number of infectious agents – such as pneumonia, tuberculosis, and salmonellosis – with every day are becoming harder to identify and treat correctly without laboratory tests, is the main cause for a massive scale of misuse and overuse of antibiotics. Approximately 30% to 50% of antibiotic use in humans is inappropriate or even unnecessary. Due to lack of diagnosis available (Time-consuming, cost, absence of infrastructure) physicians commonly prescribe antibiotics based on symptoms. However, this approach does not allow to distinguish if the disease is caused by bacteria or viruses on which drug will work and which won't. At EDAS HEALTHCARE, patent approved technology, resulting 5 years of research, developed a data-driven infectious disease diagnosis system that enables the identification of pathogens in real-time. The use of epidemiology and location-based diagnosis combined with big-data & machine learning algorithms results in over 85% accuracy (a case study results). At a fraction of the cost of laboratory tests EDAS Healthcare can provide decision support system to all physicians at any primary care service upon the first patient encounter with the ER or GP or Telemedicine, and help instantly predict the causative agent of infectious diseases (9 different viruses and 5 different bacteria to date). Targeting the infectious disease diagnostic market worth €6Bn p.a. we offer a solution for hospitals ER, Telemedicine, Homecare, and surveillance agencies. Some of them already confirmed their interest in using our service. Within the Phase 1 project we aim at preparing plans for a wide-scale clinical trials, revise our IPR protection strategy and refine our current business model.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

EDAS HEALTHCARE LTD
Contribution nette de l'UE
€ 50 000,00
Indirizzo
5 KIA CH.
12000 JERUSALEM
Israele

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00